Phaseline

Targets › C5

C5 (Complement C5): drug programs, companies and trials

8 programs from 6 companies in 41 trials: 25 Phase 3, 7 Phase 4, 7 Phase 2, 2 Phase 1; Neurology, Hematology, Ophthalmology; next expected readout Dec 2026.

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Activated downstream of classical, alternative, lectin and GZMK complement pathways..; FUNCTION: [Complement C5b]: Component of the membrane attack complex (MAC), a…. (UniProt, P01031)

Open in Phaseline: the race on C5, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaRavulizumab
Complement C5 inhibitor
C5Phase 4aHUS; Generalized Myasthenia Gravis; Delayed Graft Function; NMOSD …Jun 2027
AstellasAvacincaptad Pegol Sodium (ASP3021)
Complement C5 inhibitor
C5Phase 4Geographic AtrophyJun 2027
Regeneron PharmaceuticalsPozelimab
Complement C5 inhibitor
C5Phase 4CHAPLE Disease; Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia Gravis …Jul 2028
AstraZenecaeculizumab
Complement C5 inhibitor
C5Phase 3NMOSD; Neuromyelitis Optica Spectrum Disorder Attack; Neuromyelitis Optica Spectrum Disorders (NMOSD); Hypertensive Emergency-associated Hemolytic Uremic Syndrome …Dec 2026
RocheCrovalimab
Complement C5 inhibitor
C5Phase 3Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic SyndromeJan 2027
Regeneron PharmaceuticalsCemdisiran
Complement C5 mRNA RNAi inhibitor
C5Phase 3Paroxysmal Nocturnal Hemoglobinuria; Age-related Macular Degeneration (AMD); Generalized Myasthenia GravisJul 2028
UCB Biopharma SRLZilucoplan
Complement C5 inhibitor
C5Phase 2Generalized Myasthenia Gravis; Healthy Participants; Generalized Myasthenia Gravis (gMG); Amyotrophic Lateral SclerosisMar 2027
PPD Development, LPvilobelimab
Complement C5 inhibitor
C5Phase 2Acute Respiratory Distress Syndrome (ARDS)Jul 2028

Conditions

Paroxysmal Nocturnal Hemoglobinuria (9) Generalized Myasthenia Gravis (6) NMOSD (4) Age-related Macular Degeneration (AMD) (2) Atypical Hemolytic Uremic Syndrome (2) Acute Respiratory Distress Syndrome (ARDS) (2) Neuromyelitis Optica Spectrum Disorder Attack (2) aHUS (1) Delayed Graft Function (1) IgAN (1) Immunoglobulin A Nephropathy (1) Neuromyelitis Optica Spectrum Disorder (1)

Modalities

antibody (5), small molecule (2), mixed (1)

Companies

AstraZeneca (2) Regeneron Pharmaceuticals (2) Roche (1) Astellas (1) UCB Biopharma SRL (1) PPD Development, LP (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.